Mario Cazzola,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative,Marianna Rossi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative,Luca Malcovati,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative

View Articletitled, Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

Review Article

Unwinding the von Willebrand factor strings puzzle

Karen De Ceunynck,Simon F. De Meyer,Karen Vanhoorelbeke

View Articletitled, Unwinding the von Willebrand factor strings puzzle

Clinical Trials and Observations

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
Clinical Trials & Observations

Mary Gerrard,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Ian M. Waxman,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Richard Sposto,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Anne Auperin,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Sherrie L. Perkins,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Stanton Goldman,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Lauren Harrison,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Ross Pinkerton,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Keith McCarthy,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Martine Raphael,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Catherine Patte,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee,Mitchell S. Cairo,on behalf of the French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee

View Articletitled, Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

Supplemental data

Immunobiology

Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling

Karsten Sauer,Eugene Park,Sabine Siegemund,Anthony R. French,Joseph A. Wahle,Luise Sternberg,Stephanie Rigaud,A. Helena Jonsson,Wayne M. Yokoyama,Yina H. Huang

View Articletitled, Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling

Supplemental data

Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function

Bettina Kellersch,Thomas Brocker

View Articletitled, Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function

Supplemental data

Lymphoid Neoplasia

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

Eleanor M. Tyler,Achim A. Jungbluth,Richard J. O'Reilly,Guenther Koehne

View Articletitled, WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

Supplemental data

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

View Articletitled, Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

Supplemental data

The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies

Duan Wang,Linhao Li,Hui Yang,Stephen S. Ferguson,Maria R. Baer,Ronald B. Gartenhaus,Hongbing Wang

View Articletitled, The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies

Supplemental data

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis
Clinical Trials & Observations

Vikas Gupta,on behalf of the Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group,Sue Richards,on behalf of the Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group,Jacob Rowe,on behalf of the Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group

View Articletitled, Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

Supplemental data

Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas

Eugenio Gaudio,Francesco Paduano,Apollinaire Ngankeu,Francesca Lovat,Muller Fabbri,Hui-Lung Sun,Pierluigi Gasparini,Alexey Efanov,Yong Peng,Nicola Zanesi,Mohammed A. Shuaib,Laura Z. Rassenti,Thomas J. Kipps,Chenglong Li,Rami I. Aqeilan,Gregory B. Lesinski,Francesco Trapasso,Carlo M. Croce

View Articletitled, Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas

Supplemental data

Myeloid Neoplasia

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation

Vittorio Rosti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Laura Villani,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Roberta Riboni,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Valentina Poletto,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Elisa Bonetti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Lorenzo Tozzi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Gaetano Bergamaschi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Paolo Catarsi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Elena Dallera,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Francesca Novara,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Margherita Massa,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Rita Campanelli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Gabriela Fois,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Benedetta Peruzzi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Marco Lucioni,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Paola Guglielmelli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Alessandro Pancrazzi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Giacomo Fiandrino,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Orsetta Zuffardi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Umberto Magrini,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Marco Paulli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Alessandro M. Vannucchi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators,Giovanni Barosi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators

View Articletitled, Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation

Supplemental data

Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia

Brian Parkin,Peter Ouillette,Yifeng Li,Jennifer Keller,Cindy Lam,Diane Roulston,Cheng Li,Kerby Shedden,Sami N. Malek

View Articletitled, Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia

Supplemental data

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Clinical Trials & Observations

Matthias Horn,Ingmar Glauche,Martin C. Müller,Rüdiger Hehlmann,Andreas Hochhaus,Markus Loeffler,Ingo Roeder

View Articletitled, Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Supplemental data

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Sebastian Schwind,on behalf of the Alliance for Clinical Trials in Oncology,Colin G. Edwards,on behalf of the Alliance for Clinical Trials in Oncology,Deedra Nicolet,on behalf of the Alliance for Clinical Trials in Oncology,Krzysztof Mrózek,on behalf of the Alliance for Clinical Trials in Oncology,Kati Maharry,on behalf of the Alliance for Clinical Trials in Oncology,Yue-Zhong Wu,on behalf of the Alliance for Clinical Trials in Oncology,Peter Paschka,on behalf of the Alliance for Clinical Trials in Oncology,Ann-Kathrin Eisfeld,on behalf of the Alliance for Clinical Trials in Oncology,Pia Hoellerbauer,on behalf of the Alliance for Clinical Trials in Oncology,Heiko Becker,on behalf of the Alliance for Clinical Trials in Oncology,Klaus H. Metzeler,on behalf of the Alliance for Clinical Trials in Oncology,John Curfman,on behalf of the Alliance for Clinical Trials in Oncology,Jessica Kohlschmidt,on behalf of the Alliance for Clinical Trials in Oncology,Thomas W. Prior,on behalf of the Alliance for Clinical Trials in Oncology,Jonathan E. Kolitz,on behalf of the Alliance for Clinical Trials in Oncology,William Blum,on behalf of the Alliance for Clinical Trials in Oncology,Mark J. Pettenati,on behalf of the Alliance for Clinical Trials in Oncology,Paola Dal Cin,on behalf of the Alliance for Clinical Trials in Oncology,Andrew J. Carroll,on behalf of the Alliance for Clinical Trials in Oncology,Michael A. Caligiuri,on behalf of the Alliance for Clinical Trials in Oncology,Richard A. Larson,on behalf of the Alliance for Clinical Trials in Oncology,Stefano Volinia,on behalf of the Alliance for Clinical Trials in Oncology,Guido Marcucci,on behalf of the Alliance for Clinical Trials in Oncology,Clara D. Bloomfield,on behalf of the Alliance for Clinical Trials in Oncology

View Articletitled, inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Supplemental data

Vascular Biology

A new chromogranin A–dependent angiogenic switch activated by thrombin

Luca Crippa,Mimma Bianco,Barbara Colombo,Anna M. Gasparri,Elisabetta Ferrero,Y. Peng Loh,Flavio Curnis,Angelo Corti

View Articletitled, A new chromogranin A–dependent angiogenic switch activated by thrombin

Supplemental data

Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration

Elisa Rossi,Francisco Sanz-Rodriguez,Nelida Eleno,Annette Düwell,Francisco J. Blanco,Carmen Langa,Luisa M. Botella,Carlos Cabañas,José M. Lopez-Novoa,Carmelo Bernabeu

View Articletitled, Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration

Supplemental data

Cover Image

Cover Image

Hypothetical model for endothelial endoglin in leukocyte transmigration through the vessel endothelium. Upon inflammatory stimulation, soluble factors are released, including the chemokine CXCL12, leading to activation and endoglin-dependent extravasation of leukocytes (A). Leukocyte transmigration involves the binding of CXCL12 to its receptor CXCR4, which in turn activates the β1 integrins. Once activated, β1 integrin binds to the RGD motif of endoglin present on the endothelial cell (EC) surface, allowing the extravasation and migration of leukocytes to the inflammatory site (B). Soluble endoglin competes for the binding between leukocyte β1 integrin and endothelial membrane anchored endoglin, thus interfering with leukocyte adhesion and transmigration (C). See the article by Rossi et al on page 403.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

Table of Contents

Inside Blood

Pediatric MLBL: challenges remain
Clinical Trials & Observations

A shot in the arm for radiotherapy

Blood and endothelial cells: together through thick and thin

Blood Work

Gray platelet syndrome

Plenary Paper

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

Perspectives

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

Review Article

Unwinding the von Willebrand factor strings puzzle

Clinical Trials and Observations

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
Clinical Trials & Observations

Immunobiology

Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling

Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function

Lymphoid Neoplasia

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis
Clinical Trials & Observations

Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas

Myeloid Neoplasia

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation

Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Clinical Trials & Observations

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Vascular Biology

A new chromogranin A–dependent angiogenic switch activated by thrombin

Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Inside Blood

Pediatric MLBL: challenges remain Clinical Trials & Observations

Blood Work

Plenary Paper

Perspectives

Review Article

Clinical Trials and Observations

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy Clinical Trials & Observations

Immunobiology

Lymphoid Neoplasia

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis Clinical Trials & Observations

Myeloid Neoplasia

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia Clinical Trials & Observations

Vascular Biology

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Pediatric MLBL: challenges remain
Clinical Trials & Observations

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
Clinical Trials & Observations

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis
Clinical Trials & Observations

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Clinical Trials & Observations